Neutrophil-Lymphocyte Ratio Predicts Survival in Terminal Cancer Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Hwang, In Cheol | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.date.available | 2020-02-28T02:42:27Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016-04-01 | - |
dc.identifier.issn | 1096-6218 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8383 | - |
dc.description.abstract | Background: Neutrophil-lymphocyte count ratio (NLR) is a prognostic factor in cancer, although its prognostic significance in terminally ill cancer patients is not clear. Objective: We investigated the association of NLR with survival in patients with terminal cancer. Methods: We retrospectively investigated 205 consecutive patients with terminal cancer admitted to a palliative care unit during 2014. Results: The median value of NLR was 9.7. In univariable analysis, NLR of 10 or more was significantly associated with shorter survival and NLR further discriminated survival of each palliative prognostic index (PPI) group. In multivariable analysis, increased NLR (>= 10) was associated with shorter survival (hazards ratio [HR] 1.54, p<0.005), along with poor performance status (HR 1.55, p < 0.011), high PPI score (HR 1.59, p<0.003), and hyperbilirubinemia (HR 1.84, p < 0.001). Conclusion: Our results suggest that elevated NLR was an independent prognostic factor for poor survival in patients with terminal cancer. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MARY ANN LIEBERT, INC | - |
dc.relation.isPartOf | JOURNAL OF PALLIATIVE MEDICINE | - |
dc.subject | PALLIATIVE PROGNOSTIC SCORE | - |
dc.subject | TUMOR-INFILTRATING LYMPHOCYTES | - |
dc.subject | ILL | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | VALIDATION | - |
dc.subject | ACCURACY | - |
dc.subject | TIME | - |
dc.title | Neutrophil-Lymphocyte Ratio Predicts Survival in Terminal Cancer Patients | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000373237500017 | - |
dc.identifier.doi | 10.1089/jpm.2015.0277 | - |
dc.identifier.bibliographicCitation | JOURNAL OF PALLIATIVE MEDICINE, v.19, no.4, pp.437 - 441 | - |
dc.identifier.scopusid | 2-s2.0-84963853514 | - |
dc.citation.endPage | 441 | - |
dc.citation.startPage | 437 | - |
dc.citation.title | JOURNAL OF PALLIATIVE MEDICINE | - |
dc.citation.volume | 19 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.contributor.affiliatedAuthor | Hwang, In Cheol | - |
dc.contributor.affiliatedAuthor | Lee, Ji Sung | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.contributor.affiliatedAuthor | Cho, Eun Kyung | - |
dc.contributor.affiliatedAuthor | Shin, Dong Bok | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | PALLIATIVE PROGNOSTIC SCORE | - |
dc.subject.keywordPlus | TUMOR-INFILTRATING LYMPHOCYTES | - |
dc.subject.keywordPlus | ILL | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordPlus | ACCURACY | - |
dc.subject.keywordPlus | TIME | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.